Instil Bio (TIL) Stock Price

Instil Bio Price

NASDAQ·CLOSED
5.79
​
Market closed

Analysts set a median price target of 18.36 USD, implying 217.1% above the current price. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus.

Instil Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Instil Bio business model & stock analysis

Instil Bio Inc is a US-based company operating in industry. The company is headquartered in Dallas, Texas and currently employs 150 full-time employees. The company went IPO on 2021-03-19. Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its lead CoStAR-TIL product candidate. ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer.

Frequently asked questions about Instil Bio

Analysts currently set an average price target of 20.74 USD for the Instil Bio stock (median: 18.36 USD), implying +258.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Instil Bio stock: 5 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Instil Bio to generate revenue of 3.98 M USD and earnings per share of -1.17 USD.

Converted at the current exchange rate, the Instil Bio share trades at 5.16 EUR (5.79 USD).

The Instil Bio share (TIL) is listed on 1 stock exchanges, including: NASDAQ (TIL).

The expected revenue of Instil Bio is 3.98 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Instil Bio is -7.93 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Instil Bio is currently -4.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Instil Bio stock.

The price-to-sales ratio (P/S) of Instil Bio is currently 9.87. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Instil Bio stock.

The Eulerpool Quality Score for Instil Bio is 2/10.

The ISIN of Instil Bio is US45783C2008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Instil Bio is TIL. The ticker symbol is used to trade Instil Bio shares on the stock exchange.

Fair ValueTerminal
5.96 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 19, 2021
ISIN
US45783C2008
Cusip
45783C101
Sedol
BLFF921
Market capitalization
39.26 M USDMicro Cap
52-Week Range
PEG
-0.00
P/E ratio
P/Ee 2026
-4.95
P/Ee 2027
-0.70
P/Ee 2028
-0.52
P/Ee 2029
—
P/Ee 2030
—
P/S
P/Se
9.87
EV/EBIT
—
P/B Ratio
0.34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-35.86 %
Last updated Oct 20, 2026, 6:32 PM

Instil Bio Peer Group

Instil Bio Ticker

NASDAQ · TIL

All fundamentals and in-depth analysis of Instil Bio

Our stock analysis for Instil Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Instil Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.